- Merging lithium carbenoid homologation and enzymatic reduction: A combinative approach to the HIV-protease inhibitor Nelfinavir
-
An effective stereocontrolled synthesis of the HIV protease inhibitor Nelfinavir is reported. Two transformations were identified crucial for achieving success: the formation of a densely functionalized α-chloroketone via the homologation of a Weinreb ami
- Castoldi, Laura,Ielo, Laura,Hoyos, Pilar,Hernáiz, María J.,De Luca, Laura,Alcántara, Andrés R.,Holzer, Wolfgang,Pace, Vittorio
-
p. 2211 - 2217
(2018/03/28)
-
- Method of making HIV protease inhibitors
-
A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
- -
-
-
- Development of a continuous process for the industrial generation of diazomethane
-
The development of a safe process for the industrial generation of diazomethane is described. Diazomethane is produced and consumed in a continuous process capable of generating between 50 and 60 tonnes per year whilst the maximum inventory is maintained
- Proctor, Lee D.,Warr, Antony J.
-
p. 884 - 892
(2013/09/06)
-
- An enantioselective synthesis of (2S,3R)-3-(N-Benzyloxycarbonyl)amino-1-chloro-4-phenylthiobutan-2-ol, a central intermediate of nelfinavir
-
(2S,3R)-3-(N-Benzyloxycarbonyl)amino-1-chloro-4-phenylthiobutan-2-ol 1 is a central intermediate of nelfinavir 2, which, being a potent HIV protease inhibitor, represents one of the most clinically efficacious anti AIDS drugs. Thus, a practical enantioselective synthesis of 1 has been devised which employs sodium erythorbate 9 as a chiral starting material. Consisting of the total 14-step functional group manipulations that proceed via methyl (2S,3R)-4-hydroxy-2,3-epoxybutyrate 8, the synthetic processes can dispense with chromatographic purification and provide architecturally complex 1 in 17% overall yield under a strict control of stereochemistry.
- Ikunaka, Masaya,Matsumoto, Jun,Fujima, Yoshito,Hirayama, Yoshihiko
-
-
- Process for reducing α-amino ketones
-
The present invention has its objects to provide a method for reducing α-aminoketone derivatives under mild conditions with high stereoselectivity. This invention is a method for reducing α-aminoketone which comprises reacting an a-aminoketone derivative of general formula (1) with a compound prepared from an organoaluminum compound of general formula (4), a sulfonic acid derivative of general formula (5), and an alcohol compound of general formula (6) to give an α-aminoalcohol derivative of general formula (7)
- -
-
-
- Process for a phenylthiobutyl-isoquinoline and intermediates therefor
-
The present invention relates to a new method for making compounds of formula and intermediates for making compounds of formual II. The compounds of this invention are useful intermediates for the manufacture of pharmacologically active compounds suitable
- -
-
-
- Process for the reduction of carbonyl compounds
-
PCT No. PCT/JP97/00189 Sec. 371 Date Dec. 29, 1997 Sec. 102(e) Date Dec. 29, 1997 PCT Filed Jan. 29, 1997 PCT Pub. No. WO97/28105 PCT Pub. Date Aug. 7, 1997The present invention provides a process for reducing carbonyl compounds to hydroxy compounds, in particular stereoselectively reducing alpha -aminohaloketone derivatives, under mild conditions in an easy and simple manner, which comprises reacting a carbonyl compound of the general formula (1) with an organoaluminum compound of the general formula (4) to provide the corresponding alcohol compound of the general formula (5).
- -
-
-
- HIV protease inhibitors
-
HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
- -
-
-
- HIV protease inhibitors
-
HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain the
- -
-
-